Medlive Technology (2192) Fundamentals 2026 — P/E 14.5x, Revenue Analysis | SniperIQ
Medlive Technology (2192) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of HK$5.6B, trading at HK$7.54 on the HKSE. This SniperIQ fundamentals page covers Medlive Technology's valuation (P/E 14.5x, P/B 1.0x), profitability (net margin 52.1%), revenue (¥642M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Medlive Technology's market cap?
Medlive Technology (2192) has a market capitalization of approximately HK$5.6B, trading at HK$7.54 on the HKSE. Market cap moves with the live share price.
What is Medlive Technology's P/E ratio?
Medlive Technology's trailing twelve-month P/E ratio is 14.5x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Medlive Technology?
Medlive Technology runs a net profit margin of 52.1%, a gross margin of 60.0%, and an operating margin of 14.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Medlive Technology generate?
Medlive Technology reported revenue of ¥642M for fiscal year 2025, with net income of ¥334M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Medlive Technology pay a dividend?
Medlive Technology offers a trailing dividend yield of about 3.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Medlive Technology financially healthy?
Medlive Technology carries a debt-to-equity ratio of 0.00x and a current ratio of 19.09x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Medlive Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medlive Technology (2192) the key facts are: market cap HK$5.6B, P/E 14.5x, revenue ¥642M, 52-week range 6.31-16.84. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Medlive Technology's full fundamentals live
Get Medlive Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.